Relmada Therapeutics (RLMD) Enterprise Value (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Enterprise Value data on file, last reported at -$234.0 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 764.58% year-over-year to -$234.0 million in Q1 2026; TTM through Mar 2026 was -$234.0 million, a 764.58% decrease from a year earlier, with the FY2025 full-year figure at -$93.0 million, down 107.1% from the prior year.
• Enterprise Value for Q1 2026 stood at -$234.0 million, down from -$93.0 million in the prior quarter.
• Over the last five years, Enterprise Value for RLMD reached as high as -$13.9 million in Q3 2025 and fell as low as -$234.0 million in Q1 2026.
• Historically, Enterprise Value has averaged -$109.4 million across 5 years, with a median of -$96.3 million in 2023.
• Across the five-year window, Enterprise Value soared 74.34% in 2025 and sank 764.58% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$148.3 million in 2022, then surged by 35.06% to -$96.3 million in 2023, then jumped by 53.38% to -$44.9 million in 2024, then plunged by 107.1% to -$93.0 million in 2025, then tumbled by 151.56% to -$234.0 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$234.0 million in Q1 2026, -$93.0 million in Q4 2025, and -$13.9 million in Q3 2025.